NUV-868
- Generic Name
- NUV-868
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Cancer of OvaryProstatic CancerCastration Resistant Prostatic NeoplasmsBreast TumorCancer of the OvaryProstate CancerCancer of the ProstateTriple-negative Breast CancerCancer of BreastOvary Cancer
- Interventions
- First Posted Date
- 2022-02-23
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Nuvation Bio Inc.
- Target Recruit Count
- 82
- Registration Number
- NCT05252390
- Locations
- 🇺🇸
The University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Ellison Institute of Technology, Los Angeles, California, United States
🇺🇸Rocky Mountain Cancer Centers, LLP, Lone Tree, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath